Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)

Thumbnail
View/ Open

Show full item record
Author
Abbott, Derek J.; Blanchfield, J. Lori; Martinson, David A.; Russell, Sean C.; Taslim, Najla; Curtis II, Alan Dale; Mannie, Mark D.
Abstract
Background Vaccination strategies that elicit antigen-specific tolerance are needed as therapies for autoimmune disease. This study focused on whether cytokine-neuroantigen (NAg) fusion proteins could inhibit disease in chronic murine models of experimental autoimmune encephalomyelitis (EAE) and thus serve as potential therapeutic modalities for multiple sclerosis. Results A fusion protein comprised of murine GM-CSF as the N-terminal domain and the encephalitogenic MOG35-55 peptide as the C-terminal domain was tested as a tolerogenic, therapeutic vaccine (TTV) in the C57BL/6 model of EAE. Administration of GMCSF-MOG before active induction of EAE, or alternatively, at the onset of EAE blocked the development and progression of EAE. Covalent linkage of the GM-CSF and MOG35-55 domains was required for tolerogenic activity. Likewise, a TTV comprised of GM-CSF and PLP139-151 was a tolerogen in the SJL model of EAE. Conclusion These data indicated that fusion proteins containing GM-CSF coupled to myelin auto-antigens elicit tolerance rather than immunity.
URI
http://hdl.handle.net/10342/5669
Date
2011
Citation:
APA:
Abbott, Derek J., & Blanchfield, J. Lori, & Martinson, David A., & Russell, Sean C., & Taslim, Najla, & Curtis II, Alan Dale, & Mannie, Mark D.. (January 2011). Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE). BMC Immunology, (72-72. Retrieved from http://hdl.handle.net/10342/5669

Display/Hide MLA, Chicago and APA citation formats.

MLA:
Abbott, Derek J., and Blanchfield, J. Lori, and Martinson, David A., and Russell, Sean C., and Taslim, Najla, and Curtis II, Alan Dale, and Mannie, Mark D.. "Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)". BMC Immunology. . (72-72.), January 2011. February 22, 2020. http://hdl.handle.net/10342/5669.
Chicago:
Abbott, Derek J. and Blanchfield, J. Lori and Martinson, David A. and Russell, Sean C. and Taslim, Najla and Curtis II, Alan Dale and Mannie, Mark D., "Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)," BMC Immunology 12, no. (January 2011), http://hdl.handle.net/10342/5669 (accessed February 22, 2020).
AMA:
Abbott, Derek J., Blanchfield, J. Lori, Martinson, David A., Russell, Sean C., Taslim, Najla, Curtis II, Alan Dale, Mannie, Mark D.. Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE). BMC Immunology. January 2011; 12() 72-72. http://hdl.handle.net/10342/5669. Accessed February 22, 2020.
Collections